The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2016 | Venetoclax and the future of treatment of multiple myeloma
Shaji Kumar, MD from the Mayo Clinic, Rochester, MN discusses venetoclax and the future of treatment of multiple myeloma (MM). Venetoclax is an inhibitor of BCL-2, which is generally highly epxressed on multiple myeloma cells. According to Dr Kumar, pre-clinical studies show that venetoclax is active against myeloma cells and he further discusses the results of the Phase I trial of venetoclax as a single agent (NCT01794520) and the Phase I trial of venetoclax with bortezomib and dexamethasone (NCT01794507).
Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
